Details of the Drug Formulations

General Information of Drug (ID: DM819JF)

• Drug Name: Pemigatinib Drug Info
• Synonyms: Unii-Y6BX7BL23K; UNII-Y6BX7BL23K; Y6BX7BL23K; GTPL9767; SCHEMBL15556271; HCDMJFOHIXMBOV-UHFFFAOYSA-N; example 126 [WO2014007951]; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one; INCB54828

Indication

Disease Entry	ICD 11	Status	REF
Cholangiocarcinoma	2C12.10	Approved	[1]
Bladder cancer	2C94	Phase 2	[2]
Myeloproliferative syndrome	2A22	Phase 2	[2]

• Cross-matching ID:
  PubChem CID: 86705695
  CAS Number: 1513857-77-6
  TTD ID: D0O6UY
  ACDINA ID: D01328

Full List of Drug Formulations Containing This Drug

Pemigatinib 4.5 mg tablet

Company	Formulation ID	FDA Description
yte Corporation	F24122	Magnesium Stearate; Microcrystalline Cellulose; Sodium Starch Glycolate

Pemigatinib 9 mg tablet

Company	Formulation ID	FDA Description
yte Corporation	F24123	Magnesium Stearate; Microcrystalline Cellulose; Sodium Starch Glycolate

Pemigatinib 13.5 mg tablet

Company	Formulation ID	FDA Description
yte Corporation	F24124	Magnesium Stearate; Microcrystalline Cellulose; Sodium Starch Glycolate

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)